Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Milena Tocut, Yehuda Shoenfeld & Gisele Zandman-Goddard. (2020) Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs 29:10, pages 1151-1162.
Read now
Read now
Huza Zhang, William Chambers, Savino Sciascia & Maria J. Cuadrado. (2016) Emerging therapies in systemic lupus erythematous: from clinical trial to the real life. Expert Review of Clinical Pharmacology 9:5, pages 681-694.
Read now
Read now
Morton A. Scheinberg, Colin M. Hislop & Renee S. Martin. (2016) Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opinion on Biological Therapy 16:5, pages 723-733.
Read now
Read now
Mariana Postal, Nailú Angélica Sinicato, Simone Appenzeller & Timothy B. Niewold. (2016) Drugs in early clinical development for Systemic Lupus Erythematosus. Expert Opinion on Investigational Drugs 25:5, pages 573-583.
Read now
Read now
Andreia Vilas-Boas, Jyoti Bakshi & David A Isenberg. (2015) What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?. Expert Review of Clinical Immunology 11:10, pages 1093-1107.
Read now
Read now
Hanan Al Rayes & Zahi Touma. (2014) Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Design, Development and Therapy 8, pages 2303-2310.
Read now
Read now
Articles from other publishers (6)
Lucia Martin‐Gutierrez, Junjie Peng, Nicolyn L. Thompson, George A. Robinson, Meena Naja, Hannah Peckham, WingHan Wu, Hajar J’bari, Nyarko Ahwireng, Kirsty E. Waddington, Claire M. Bradford, Giulia Varnier, Akash Gandhi, Rebecca Radmore, Vivek Gupta, David A. Isenberg, Elizabeth C. Jury & Coziana Ciurtin. (2021) Stratification of Patients With Sjögren’s Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications. Arthritis & Rheumatology 73:9, pages 1626-1637.
Crossref
Crossref
Virginie Jadot, Jean-Marie Krzesinski, Christian Von Frenckell, Christophe Bovy & Antoine Bouquegneau. (2018) La néphropathie lupique : les nouvelles perspectives de traitement. Néphrologie & Thérapeutique 14:1, pages 1-12.
Crossref
Crossref
Lunhua Liu, Windy Rose Allman, Adam Steven Coleman, Kazuyo Takeda, Tsai-Lien Lin & Mustafa Akkoyunlu. (2018) Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse. Scientific Reports 8:1.
Crossref
Crossref
Jennifer Witcher, Roy Fleischmann, Vishala L. Chindalore, Ryan J. Hansen, Leijun Hu, David Radtke, James Voelker, Elisa Gomez & Juliet McColm. (2016) Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. British Journal of Clinical Pharmacology 81:5, pages 908-917.
Crossref
Crossref
Jyoti Bakshi, Mediola Ismajli & Anisur Rahman. (2015) New therapeutic avenues in SLE. Best Practice & Research Clinical Rheumatology 29:6, pages 794-809.
Crossref
Crossref
Judy H Cho & Marc Feldman. (2015) Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nature Medicine 21:7, pages 730-738.
Crossref
Crossref